NeuroKinetic Medical stops Stage I & II pressure injuries before they progress — using proprietary electrical stimulation proven in 412-patient RCT trials across hospital, SNF, and home settings.
Navigate to any section to learn more about who we are, why this moment matters, what Prelivia does, and how it's proven.
Whether you’re a clinician, health system leader, or investor — we’d like to talk.
Get in touchFounded on 15+ years of electrical stimulation science, cleared by the FDA and Health Canada, and now executing on US commercial launch.
NeuroKinetic Medical is a medtech company transforming outcomes for patients at risk of pressure injuries — a costly, largely preventable clinical burden affecting millions of patients annually across hospital, long-term care, and home health settings.
Our flagship platform, Prelivia™, targets Stage I and Stage II pressure wounds — the 98.7% of pressure injuries that are still reversible — before they progress to the costly, unreimbursed Stage III and IV events that devastate patients and health system finances alike.
Built on 15+ years of electrical stimulation IP through our acquisition of Rehabtronics Inc., and cleared by the FDA and Health Canada, we are now executing on US commercial launch while advancing the next generation of the platform.
Explore our clinical evidence, platform features, or reach out directly.
Four forces have aligned to make NeuroKinetic not just possible, but necessary — today.
Edge technology and AI inference is now part of hospital and SNF infrastructure — creating the connected, sensor-enabled environment that NeuroKinetic leverages for monitoring and intervention.
CMS penalties and litigation costs now make pressure injuries a P&L line item. New regulations extend penalties to Stage II injuries. The average nursing home pressure ulcer lawsuit pays out $500K+.
Adults 65+ will exceed 20% of the US population by 2030. ICU admissions, post-surgical patients, and SNF long-stay residents are all rising, making prevention one of the highest-yield interventions available.
Nurse-to-patient ratios are at historic lows — frontline automation of intervention and monitoring is no longer optional. With Prelivia, the same preventive outcome requires approximately 10 minutes of nursing time per patient per session.
Platform features built to solve every one of these problems directly.
A bedside durable unit plus proprietary single-use consumable pads — FDA 510(k) cleared and deployable in hospital, long-term care, and home settings with minimal nursing burden.
Prelivia targets the 98.7% of pressure injuries that are still reversible — before they advance to Stage III and IV. It works in every setting, with every patient population, with 100% patient acceptance in all clinical trials.
Stops Stage I & II pressure wounds from progressing to costly, unreimbursed Stage III & IV events. Intervenes before visible breakdown — the 98.7% window where injuries are still reversible.
Addresses the sacrum and buttocks — 59% of all pressure wound sites. Electrical stimulation restores blood flow and oxygenation to at-risk tissue, preventing ischemic injury before it forms.
Electrical stimulation works regardless of staffing ratios or nurse compliance. ~10 minutes of nursing time per patient vs. 2+ hours for traditional turning protocols.
Portable and designed for ease-of-use across hospital, long-term care, remote, and home healthcare settings. 250 nurses trained to date — with 100% patient acceptance in all clinical trials.
Roadmap includes comprehensive wound and venous ulcer management — significantly expanding the addressable market beyond pressure injuries.
8 patents issued, 2 pending. 5 peer-reviewed publications. 80% less tissue injury in pre-clinical and clinical studies. 28% increase in tissue oxygenation (spO₂).
Our clinical team will walk you through the platform, share outcomes data for your patient population, and support your evaluation process.
Request a demoA rigorous, peer-reviewed evidence base supporting the safety and efficacy of Prelivia — from pre-clinical studies through a 412-patient prospective RCT.
Animal & human studies completed. 68 patients across ICU, Acute & LTAC settings. Published in Annals of Biomedical Engineering and Journal of Applied Physiology. 28% increase in tissue oxygenation. 80% reduction in tissue damage.
Randomized controlled trial across 3 Magnet-designated hospital systems. 87% HAPI reduction, Stage II+. 91% sensitivity at 18 hours. Zero pressure injuries in treated patients across all completed trial arms. 100% patient acceptance.
Core science peer-reviewed and replicated. RCT submitted to WOUND journal — peer review in progress. IRB approved. NCT registered.
Per 300-bed hospital deployment — first-year analysis
Full clinical dossier, peer-to-peer investigator discussions, or facility evaluation support.
Contact medical affairsCompetition is fragmented, reactive, and single-point. NeuroKinetic is the only end-to-end AI platform for pressure injury prevention and management.
Prelivia stops injuries from forming. Every competitor — wound dressings, alternating pressure mats, turning protocols — treats symptoms after the fact.
Electrical stimulation works regardless of staffing ratios or nurse compliance. This is the critical advantage in understaffed SNFs and hospitals.
Prelivia works in acute care hospitals, SNFs, long-term care, and home health — a single platform that follows the patient across the entire care continuum.
FDA 510(k) cleared and ISO certified. 8 patents issued, 2 pending — 15+ years of foundational electrical stimulation IP. Commercially deployable today in the US and Canada.
| Solution | Prevents Injury | Adaptive | No Staff Reliance | Recurring Revenue | SNF-Ready |
|---|---|---|---|---|---|
| Prelivia™ (NK) | ✓ | ✓ | ✓ | ✓ | ✓ |
| Alternating pressure mat | ~ | — | — | ~ | ~ |
| Manual turning protocols | ~ | — | — | — | ✓ |
| Wound dressings (reactive) | — | — | — | ✓ | ✓ |
| Vibration/offloading devices | ~ | — | ~ | — | ~ |
87% HAPI reduction. 3.28× ROI. 5 peer-reviewed publications. The data backs every claim.
Clinical depth + commercial execution + technology leadership — the three capabilities that matter most in medtech commercialization.
We’re building a category-defining company. Reach out to discuss clinical collaborations, commercial partnerships, or career opportunities.
Get in touchPaid pilots, strategic industry relationships, and regulatory clearances across three jurisdictions.
Whether you’re a health system, device company, distributor, or research institution — we’d like to hear from you.
Contact usClinical insights, research updates, and perspectives from our team.
Pressure ulcers represent a significant challenge in modern healthcare, particularly among immobile and elderly patients. Despite advances in medical technology and preventive protocols, they remain associated with prolonged hospitalization, increased healthcare costs, and reduced quality of life.
While clinical guidelines emphasize prevention and structured care, real-life cases often reveal gaps between theoretical knowledge and everyday practice — especially in home care settings.
Pressure ulcers develop because of prolonged pressure on soft tissues, most commonly over bony prominences such as the sacrum, heels, hips, and elbows. Prolonged pressure leads to impaired blood circulation, tissue ischemia, and eventual necrosis.
Risk factors include:
Clinical classification ranges from early-stage skin redness to deep tissue damage involving muscles and bones. Early recognition is critical, as progression can be rapid and complications severe.
A practical example illustrates this issue clearly: An elderly patient, following a stroke, remained bedridden for several months under family care. Despite genuine effort and dedication, a pressure ulcer developed in the sacral region. The delay in detection was primarily due to insufficient repositioning and limited awareness of early warning signs. By the time professional care was introduced, the wound had already progressed to an advanced stage, requiring intensive treatment.
Effective management of pressure ulcers requires more than local wound care. It involves a comprehensive and coordinated strategy:
Evidence from clinical practice shows that combined approaches, supported by advanced wound care technologies and used alongside standard care, lead to better outcomes compared to conservative treatment alone.
Modern treatment emphasizes the importance of a multidisciplinary approach, involving physicians, nurses, and caregivers. Key elements include:
Studies show that consistent application of these protocols can significantly reduce the incidence of pressure ulcers in clinical settings.
Although pressure ulcers are often discussed in clinical terms, their impact extends far beyond physical health. Patients frequently experience pain and discomfort, emotional distress, and loss of dignity and independence.
Continuous support, communication, and empathy play a crucial role in restoring a patient’s sense of self-worth. Healing is not purely physical.
Prevention remains the most effective approach to managing pressure ulcers. Key preventive measures include:
Clinical data consistently demonstrate that institutions applying structured prevention protocols achieve significantly better outcomes, including reduced incidence and improved healing rates.
Pressure ulcers remain a complex medical and social issue, requiring both clinical expertise and human-centered care. Bridging the gap between professional knowledge and everyday caregiving is essential — particularly in home environments where many cases originate.
Timely intervention, education, and a multidisciplinary approach not only improve clinical outcomes but also preserve patient dignity and quality of life.